

For treatment of carotid artery stenosis

Antithrombogenic coating *

Different device configurations for tailored treatment options


Perfect flexibility and high plaque coverage

 $\hbox{* The antithrombogenic properties were demonstrated in non-clinical tests.}$




ORDERING INFORMATION | CARESTO® heal

Labelled CARESTO® heal Dimensions (mm)	Reference Number	Unconstrained Device Diameter (mm)	Unconstrained Device Length (mm)	Recommended Vessel Diameter (mm)	Required/ Recommended Catheters for Delivery		
6.0 × 30	01-005301	6.3	23	4.0 – 6.0			
6.0 × 40	01-005302	6.3	30	4.0 – 6.0	NeuroSlider® 52 DLC (ID: 0.052")		
6.0 × 50	01-005303	6.3	37	4.0 – 6.0			
8.0 × 30	01-005311	8.3	24	6.0 – 8.0			
8.0 × 40	01-005312	8.3	32	6.0 – 8.0			
8.0 × 50	01-005313	8.3	40	6.0 – 8.0			
8.0 × 60	01-005314	8.3	47	6.0 – 8.0			
10.0 × 30	01-005321	10.3	25	8.0 – 10.0			
10.0 × 40	01-005322	10.3	33	8.0 – 10.0			
10.0 × 50	01-005323	10.3	41	8.0 – 10.0			
10.0 × 60	01-005324	10.3	49	8.0 – 10.0			



Labelled CARESTO® heal Dimensions (mm)	Reference Number	Unconstrained Device Diameter dist. / prox. (mm)	Unconstrained Device Length (mm)	Recommended Vessel Diameter dist. / prox. (mm)	Required/ Recommended Catheters for Delivery	
6.0 / 8.0 × 29	01-005351	6.3 / 8.3	29	4.0 - 6.0 / 6.0 - 8.0	NeuroSlider® 52 DLC (ID: 0.052")	
6.0 / 8.0 × 35	01-005352	6.3 / 8.3	35	4.0 - 6.0 / 6.0 - 8.0		
6.0 / 8.0 × 41	01-005353	6.3 / 8.3	41	4.0 - 6.0 / 6.0 - 8.0		
8.0 / 10.0 × 29	01-005361	8.3 / 10.3	29	6.0 - 8.0 / 8.0 - 10.0		
8.0 / 10.0 × 36	01-005362	8.3 / 10.3	36	6.0 - 8.0 / 8.0 - 10.0		
8.0 / 10.0 × 43	01-005363	8.3 / 10.3	43	6.0 - 8.0 / 8.0 - 10.0		



All changes or modifications, may they be technical or other, or changes in the availability of products are expressively reserved. Not available for sale in the United States.







NeuroSlider® DLC (Micro)Catheter



Superior torqueability and pushability

Smooth and safe device delivery

Long-lasting tip shape retention




AC_Data sheet_NeuroSlider DLC (LMR) EN 05/2023 (int.)

ORDERING INFORMATION | NeuroSlider® DLC

Product Name	Reference Number	ID (Inch)	OD dist. / prox. (French)	Usable Length (cm)	Tip Shape	Tip Marker
	01-000282	0.0165	1.9 / 2.3	155	Straight (shapeable)	2
NeuroSlider® 17 DLC	01-000283	0.0165	1.9 / 2.3	160	Straight (shapeable)	2
	01-000284	0.0165	1.9 / 2.3	167	Straight (shapeable)	2
	01-000292	0.021	2.3 / 2.6	155	Straight (shapeable)	2
NeuroSlider® 21 DLC	01-000293	0.021	2.3 / 2.6	160	Straight (shapeable)	2
	01-000294	0.021	2.3 / 2.6	167	Straight (shapeable)	2
NeuroSlider® 27 DLC	01-000276	0.027	3.0 / 3.1	155	Straight (shapeable)	1
NeuroSlider® 27 DLC pro*	01-000277	0.027	3.0 / 3.1	155	Straight (shapeable)	1
	01-000262	0.039	4.0 / 4.1	125	Straight (shapeable)	1
NeuroSlider® 39 DLC	01-000263	0.039	4.0 / 4.1	135	Straight (shapeable)	1
	01-000264	0.039	4.0 / 4.1	145	Straight (shapeable)	1
	01-000252	0.052	5.0 / 5.1	105	Straight (shapeable)	1
	01-000253	0.052	5.0 / 5.1	115	Straight (shapeable)	1
NeuroSlider® 52 DLC*	01-000254	0.052	5.0 / 5.1	125	Straight (shapeable)	1
	01-000255	0.052	5.0 / 5.1	135	Straight (shapeable)	1
	01-000256	0.052	5.0 / 5.1	145	Straight (shapeable)	1
	01-000257	0.052	5.0 / 5.1	105	Straight (shapeable)	1
	01-000258	0.052	5.0 / 5.1	115	Straight (shapeable)	1
NeuroSlider® 52 DLC pro*	01-000259	0.052	5.0 / 5.1	125	Straight (shapeable)	1
	01-000260	0.052	5.0 / 5.1	135	Straight (shapeable)	1
	01-000261	0.052	5.0 / 5.1	145	Straight (shapeable)	1

^{*} For availability and device compatibility please contact your local representative from Acandis®



All changes or modifications, may they be technical or other, or changes in the availability of products are expressively reserved. Not available for sale in the United States.








ACCERO® heal

DERIVO® 2heal® Embolisation Device



ACCLINO® heal Stent



CREDO® heal **Stent**



CARESTO® heal Stent



Next Generation of Antithrombogenic Coating

Antithrombogenic

Anti-inflammatory

Endothelialisation-promoting





An entirely new approach for rapid healing of vascular lesions after device implantation

The HEAL Technology imitates the last step of natural haemostasis by forming a thin and fully cured fibrin network on the implant surface.

In conjunction with covalently bound heparin to the fibrin network, the HEAL coating exhibits an unique combination of antithrombogenic, anti-inflammatory and endothelialisation-promoting properties.



Prof. Dr. Meltem Avci-Adali Research Director Thoracic and Cardiovascular Surgery, University Hospital Tübingen, Germany


"In preclinical studies, HEAL coated devices have shown significant minimisation of thrombogenic and inflammatory responses. Together with the simultaneous potential to promote endothelialisation, HEAL technology represents a promising strategy to improve the treatment of patients with endovascular diseases, such as intracranial aneurysms."


Antithrombogenic


- reduced risk of device thrombosis

The fibrin-heparin coating passivates the surface and reduces platelet activation and coagulation cascade.

Deposits from the blood and thrombogenicity of vascular devices are significantly reduced. Thereby the coating is non-eluting and has no pharmacological effect.









SEM images of uncoated and HEAL coated devices after incubation in a Chandler Loop with human blood



- reduced risk of inflammatory reactions

Fibrin network

Heparin

Natural fibrin network before endothelialisation

SC5b-9 is a plasma protein from the complement system. *In vitro* investigations indicate a very low activation of the immune system with HEAL coated devices comparable to the control group (blood without device).

The complement system is significantly less activated by DERIVO® 2heal® compared to other commercially available coated flow diverters.




Atomic Force

Microscope image


of HEAL coated glass


Wound healing assay using HUVECs* indicate that HEAL coated nitinol surfaces do not impede endothelial cell proliferation compared to an uncoated TiO2 surface. Moreover, the fibrin-heparin coating promotes endothelial cell covering.

*Human Umibical Vein Endothelial Cells.



In vitro investigation of SC5b-9





Wound healing assay using HUVECs